Ambee Pharmaceuticals (DHA:AMBEEPHA) Cash Flow from Financing: BDT0.00 Mil (TTM As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:AMBEEPHA Ambee Pharmaceuticals Plc DHA:AMBEEPHA
18 GF Score
Price BDT819.70
View Full Analysis

What is Ambee Pharmaceuticals Cash Flow from Financing?

Ambee Pharmaceuticals DHA:AMBEEPHA +0.61% 18 Cash Flow from Financing is BDT0.00 Mil as of . 20. GuruFocus rates DHA:AMBEEPHA with a GF Score™ of 18/100.

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in . 20, Ambee Pharmaceuticals paid BDT0.00 Mil more to buy back shares than it received from issuing new shares. It received BDT0.00 Mil from issuing more debt. It paid BDT0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received BDT0.00 Mil from paying cash dividends to shareholders. It received BDT0.00 Mil on other financial activities. In all, Ambee Pharmaceuticals spent BDT0.00 Mil on financial activities for the six months ended in . 20.


Ambee Pharmaceuticals  (DHA:AMBEEPHA) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Ambee Pharmaceuticals's issuance of stock for the six months ended in . 20 was BDT0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Ambee Pharmaceuticals's repurchase of stock for the six months ended in . 20 was BDT0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Ambee Pharmaceuticals's net issuance of debt for the six months ended in . 20 was BDT0.00 Mil. Ambee Pharmaceuticals received BDT0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Ambee Pharmaceuticals's net issuance of preferred for the six months ended in . 20 was BDT0.00 Mil. Ambee Pharmaceuticals paid BDT0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Ambee Pharmaceuticals's cash flow for dividends for the six months ended in . 20 was BDT0.00 Mil. Ambee Pharmaceuticals received BDT0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Ambee Pharmaceuticals's other financing for the six months ended in . 20 was BDT0.00 Mil. Ambee Pharmaceuticals received BDT0.00 Mil on other financial activities.


Ambee Pharmaceuticals Cash Flow from Financing Related Terms


Ambee Pharmaceuticals Cash Flow from Financing Historical Data

* Premium members only.

The historical data trend for Ambee Pharmaceuticals's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ambee Pharmaceuticals Cash Flow from Financing Chart

Ambee Pharmaceuticals Annual Data
Trend
Cash Flow from Financing

Ambee Pharmaceuticals Semi-Annual Data
Cash Flow from Financing
DHA:AMBEEPHA
18GF Score
Ambee Pharmaceuticals Plc DHA:AMBEEPHA
Cash Flow from Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ambee Pharmaceuticals Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Ambee Pharmaceuticals's Cash from Financing for the fiscal year that ended in . 20 is calculated as:

Ambee Pharmaceuticals's Cash from Financing for the quarter that ended in . 20 is:


For stock reported annually, GuruFocus uses latest annual data as the TTM data. Cash Flow from Financing for the trailing twelve months (TTM) ended in . 20 was BDT0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Financing of BDT0.00 Mil mean?
Ambee Pharmaceuticals (DHA:AMBEEPHA) has a Cash Flow from Financing of BDT0.00 Mil as of . 20. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Ambee Pharmaceuticals and its competitors.
Is Ambee Pharmaceuticals' Cash Flow from Financing too high?
Ambee Pharmaceuticals' current Cash Flow from Financing is BDT0.00 Mil. Overall, Ambee Pharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Ambee Pharmaceuticals' Cash Flow from Financing compare to IMNPQ?
Ambee Pharmaceuticals' Cash Flow from Financing of BDT0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Drug Manufacturers company?
A good Cash Flow from Financing depends on the Drug Manufacturers industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Ambee Pharmaceuticals and its competitors. Ambee Pharmaceuticals's current Cash Flow from Financing is BDT0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ambee Pharmaceuticals stock overvalued right now?
Ambee Pharmaceuticals (DHA:AMBEEPHA) has a current Cash Flow from Financing of BDT0.00 Mil. The current Cash Flow from Financing is BDT0.00 Mil. Ambee Pharmaceuticals' overall GF Score™ is 18/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Ambee Pharmaceuticals (DHA:AMBEEPHA), the current Cash Flow from Financing is BDT0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ambee Pharmaceuticals Business Description

Address 184/1 Tejgaon Industrial Area, Dhaka, BGD, 1208
Ambee Pharmaceuticals Plc formerly Ambee Pharmaceuticals Ltd manufactures a wide range of pharmaceutical products in Bangladesh. It is engaged in the business of manufacturing drugs and medicine and sales. Its products are sold in the form of tablets, capsules, liquids, gels, and injectables.
18GF Score

Get the complete analysis for DHA:AMBEEPHA

Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT819.70
Price